Key Highlights
- GeneDx Holdings shares are trading up 10.69% today, continuing a rally sparked by last week's Q2 results.
- Second-quarter exome/genome test volumes reached 30,785, up 32% year-over-year.
- Total revenue reached $114.4 million, with commercial payer coverage expanding to roughly 97% of the covered population.
- Management raised full-year revenue guidance and reaffirmed positive adjusted EBITDA expectations.
Why Is GeneDx Holdings Stock Rising Today?
GeneDx Holdings (NASDAQ:WGS) shares are climbing today as investors continue to digest strong second-quarter results reported on August 3. Exome and genome test volumes rose 32% year-over-year to 30,785, while total revenue reached $114.4 million, driving a return to positive adjusted profitability for the quarter. Commercial payer coverage also expanded meaningfully, jumping from roughly 47% to approximately 97% of the covered population, a shift management flagged as reinforcing confidence in the company's reimbursement and scale trajectory.
GeneDx Holdings is a Stamford, Connecticut-based genomics leader with a primary focus on pediatric, rare disease, and rare disease diagnostics services, holding a proprietary database of more than 600,000 clinical exomes that management says delivers a diagnostic rate significantly above the industry average.
Broader Genomics and Diagnostics Momentum
GeneDx's rally today fits into a broader wave of strength across genomics and diagnostics names this week. Peers Personalis (NASDAQ:PSNL) and Agilon Health (NYSE:AGL) have also posted sharp gains recently, as the sector benefits from improving reimbursement trends and rising testing volumes across specialty diagnostics providers. GeneDx additionally announced upcoming investor conference appearances at Canaccord Genuity and Wells Fargo events, which investors are watching for further visibility into the growth trajectory.
Management also reaffirmed full-year 2026 guidance and cited broader healthcare sector strength as a supportive backdrop, alongside improving earnings trends and a wave of M&A activity across the space.
Conclusion
GeneDx Holdings shares are extending gains today as the market continues to reward strong genome test volume growth, expanding payer coverage, and a return to profitability. The stock's move also reflects a broader rally across genomics and diagnostics names this week as the sector benefits from improving reimbursement dynamics.
This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.






Please wait processing your request...